Retinal microangiopathy in a mouse model of inducible mural cell loss

American Journal of Pathology

Volumn 184, Issue 10, 2014, Pages 2618-2626

  Valdez, Cammi N ^a   Arboleda Velasquez, Joseph F ^a   Amarnani, Dhanesh S ^a   Kim, Leo A ^a   D'Amore, Patricia A ^a,b  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL DEATH; CELL LOSS; CONTROLLED STUDY; DIABETIC RETINOPATHY; MICROANEURYSM; MICROANGIOPATHY; MOUSE; NONHUMAN; PERICYTE; PHENOTYPE; PRIORITY JOURNAL; RETINA BLOOD VESSEL; RETINA DEGENERATION; RETINA DISEASE; RETINA NEOVASCULARIZATION; RETINAL MICROANGIOPATHY; ANIMAL; C57BL MOUSE; CAPILLARY; DISEASE MODEL; HUMAN; MALE; MICROVASCULATURE; PATHOLOGY; RETINA; TRANSGENIC MOUSE;

ANIMALS; CAPILLARIES; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROVESSELS; PERICYTES; RETINA; RETINAL DEGENERATION; RETINAL VESSELS;

EID: 84919372584     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2014.06.011     Document Type: Article

References (69)

1. Roy MS, Klein R, O'Colmain BJ, Klein BE, Moss SE, Kempen JH: The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch Ophthalmol 2004, 122:546-551.
2. Cheung N, Mitchell P, Wong TY: Diabetic retinopathy. Lancet 2010, 376:124-136.
3. Cogan DG: Diabetic retinopathy. N Engl J Med 1964, 270:787-788.
4. Antonetti DA, Klein R, Gardner TW: Diabetic retinopathy. N Engl J Med 2012, 366:1227-1239.
5. Taylor E, Dobree JH: Proliferative diabetic retinopathy. Site and size of initial lesions. Br J Ophthalmol 1970, 54:11-18.
6. Sapieha P, Hamel D, Shao Z, Rivera JC, Zaniolo K, Joyal JS, Chemtob S: Proliferative retinopathies: Angiogenesis that blinds. Int J Biochem Cell Biol 2010, 42:5-12.
7. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000, 342:381-389.
8. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994, 118:445-450.
9. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994, 331: 1480-1487.
10. Miller JW, Adamis AP, Aiello LP: Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997, 13:37-50.
11. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP: A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004, 18:1450-1452.
12. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC, Quinn PG, Sandirasegarane L, Simpson IA; JDRF Diabetic Retinopathy Center Group: Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006, 55:2401-2411.
13. Avery RL: Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006, 26:352-354.
14. Mason JO 3rd, Nixon PA, White MF: Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006, 142:685-688.
15. Gologorsky D, Thanos A, Vavvas D: Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy. Mediators Inflamm 2012, 2012:629452.
16. Jardeleza MS, Miller JW: Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin Ophthalmol 2009, 24:87-92.
17. Newman DK: Surgical management of the late complications of proliferative diabetic retinopathy. Eye (Lond) 2010, 24:441-449.
18. Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, Jorge R: Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008, 86:385-389.
19. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010, 33:2399-2405.
20. Sohn EH, He S, Kim LA, Salehi-Had H, Javaheri M, Spee C, Dustin L, Hinton DR, Eliott D: Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1. Arch Ophthalmol 2012, 130:1127-1134.
21. Cogan DG, Kuwabara T: The mural cell in perspective. Arch Ophthalmol 1967, 78:133-139.
22. Speiser P, Gittelsohn AM, Patz A: Studies on diabetic retinopathy. 3. Influence of diabetes on intramural pericytes. Arch Ophthalmol 1968, 80:332-337.
23. Cogan DG, Toussaint D, Kuwabara T: Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 1961, 66:366-378.
24. Engerman RL: Pathogenesis of diabetic retinopathy. Diabetes 1989, 38:1203-1206.
25. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984, 102:527-532.
26. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984, 102:520-526.
27. Hammes HP, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Brownlee M, Deutsch U: Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002, 51:3107-3112.
28. Sasongko MB, Wong TY, Nguyen TT, Cheung CY, Shaw JE, Wang JJ: Retinal vascular tortuosity in persons with diabetes and diabetic retinopathy. Diabetologia 2011, 54:2409-2416.
29. Robinson R, Barathi VA, Chaurasia SS, Wong TY, Kern TS: Update on animal models of diabetic retinopathy: From molecular approaches to mice and higher mammals. Dis Model Mech 2012, 5:444-456.
30. Armulik A, Genove G, Betsholtz C: Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 2011, 21:193-215.
31. Lindahl P, Johansson BR, Leveen P, Betsholtz C: Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277:242-245.
32. Enge M, Bjarnegard M, Gerhardt H, Gustafsson E, Kalen M, Asker N, Hammes HP, Shani M, Fassler R, Betsholtz C: Endothelium- specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J 2002, 21:4307-4316.
33. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV: Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010, 68:409-427.
34. Armulik A, Genove G, Mae M, Nisancioglu MH, Wallgard E, Niaudet C, He L, Norlin J, Lindblom P, Strittmatter K, Johansson BR, Betsholtz C: Pericytes regulate the blood-brain barrier. Nature 2010, 468:557-561.
35. Buch T, Heppner FL, Tertilt C, Heinen TJ, Kremer M, Wunderlich FT, Jung S, Waisman A: A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat Methods 2005, 2:419-426.
36. Indra AK, Warot X, Brocard J, Bornert JM, Xiao JH, Chambon P, Metzger D: Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res 1999, 27:4324-4327.
37. Wirth A, Benyo Z, Lukasova M, Leutgeb B, Wettschureck N, Gorbey S, Orsy P, Horvath B, Maser-Gluth C, Greiner E, Lemmer B, Schutz G, Gutkind JS, Offermanns S: G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. Nat Med 2008, 14:64-68.
38. Gerhardinger C, Dagher Z, Sebastiani P, Park YS, Lorenzi M: The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes 2009, 58: 1659-1667.
39. Laver NM, Robison WG Jr, Pfeffer BA: Novel procedures for isolating intact retinal vascular beds from diabetic humans and animal models. Invest Ophthalmol Vis Sci 1993, 34:2097-2104.
40. Zhang Q, Guy K, Pagadala J, Jiang Y, Walker RJ, Liu L, Soderland C, Kern TS, Ferry R Jr, He H, Yates CR, Miller DD, Steinle JJ: Compound 49b prevents diabetes-induced apoptosis through increased IGFBP-3 levels. Invest Ophthalmol Vis Sci 2012, 53:3004-3013.
41. Kuwabara T, Cogan DG: Studies of retinal vascular patterns. I. Normal architecture. Arch Ophthalmol 1960, 64:904-911.
42. Kuwabara T, Cogan DG: Retinal vascular patterns. VI. Mural cells of the retinal capillaries. Arch Ophthalmol 1963, 69:492-502.
43. Kern TS, Engerman RL: A mouse model of diabetic retinopathy. Arch Ophthalmol 1996, 114:986-990.
44. Barber AJ, Antonetti DA, Kern TS, Reiter CE, Soans RS, Krady JK, Levison SW, Gardner TW, Bronson SK: The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 2005, 46:2210-2218.
45. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA: Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS One 2008, 3:e3554.
46. Brockschnieder D, Lappe-Siefke C, Goebbels S, Boesl MR, Nave KA, Riethmacher D: Cell depletion due to diphtheria toxin fragment A after Cre-mediated recombination. Mol Cell Biol 2004, 24:7636-7642.
47. Joyce NC, Haire MF, Palade GE: Contractile proteins in pericytes. II. Immunocytochemical evidence for the presence of two isomyosins in graded concentrations. J Cell Biol 1985, 100:1387-1395.
48. Collins JA, Schandi CA, Young KK, Vesely J, Willingham MC: Major DNA fragmentation is a late event in apoptosis. J Histochem Cytochem 1997, 45:923-934.
49. Wilkinson-Berka JL, Babic S, De Gooyer T, Stitt AW, Jaworski K, Ong LG, Kelly DJ, Gilbert RE: Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am J Pathol 2004, 164:1263-1273.
50. vom Hagen F, Feng Y, Hillenbrand A, Hoffmann S, Shani M, Deutsch U, Hammes HP: Early loss of arteriolar smooth muscle cells: More than just a pericyte loss in diabetic retinopathy. Exp Clin Endocrinol Diabetes 2005, 113:573-576.
51. Gardiner TA, Archer DB, Curtis TM, Stitt AW: Arteriolar involvement in the microvascular lesions of diabetic retinopathy: Implications for pathogenesis. Microcirculation 2007, 14:25-38.
52. Karram K, Chatterjee N, Trotter J: NG2-expressing cells in the nervous system: role of the proteoglycan in migration and glial-neuron interaction. J Anat 2005, 207:735-744.
53. Kinyoun JL, Martin DC, Fujimoto WY, Leonetti DL: Ophthalmoscopy versus fundus photographs for detecting and grading diabetic retinopathy. Invest Ophthalmol Vis Sci 1992, 33:1888-1893.
54. Rakoczy EP, Ali Rahman IS, Binz N, Li CR, Vagaja NN, dePinho M, Lai CM: Characterization of a mouse model of hyperglycemia and retinal neovascularization. Am J Pathol 2010, 177:2659-2670.
55. Orlidge A, D'Amore PA: Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol 1987, 105: 1455-1462.
56. Sato Y, Rifkin DB: Inhibition of endothelial cell movement by pericytes and smooth muscle cells: Activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol 1989, 109:309-315.
57. Stratman AN, Malotte KM, Mahan RD, Davis MJ, Davis GE: Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation. Blood 2009, 114:5091-5101.
58. Stratman AN, Schwindt AE, Malotte KM, Davis GE: Endothelialderived PDGF-BB and HB-EGF coordinately regulate pericyte recruitment during vasculogenic tube assembly and stabilization. Blood 2010, 116:4720-4730.
59. Saunders WB, Bohnsack BL, Faske JB, Anthis NJ, Bayless KJ, Hirschi KK, Davis GE: Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. J Cell Biol 2006, 175: 179-191.
60. Davis GE, Senger DR: Extracellular matrix mediates a molecular balance between vascular morphogenesis and regression. Curr Opin Hematol 2008, 15:197-203.
61. Midena E, Segato T, Radin S, di Giorgio G, Meneghini F, Piermarocchi S, Belloni AS: Studies on the retina of the diabetic db/db mouse. I. Endothelial cell-pericyte ratio. Ophthalmic Res 1989, 21:106-111.
62. Martin PM, Roon P, Van Ells TK, Ganapathy V, Smith SB: Death of retinal neurons in streptozotocin-induced diabetic mice. Invest Ophthalmol Vis Sci 2004, 45:3330-3336.
63. Feit-Leichman RA, Kinouchi R, Takeda M, Fan Z, Mohr S, Kern TS, Chen DF: Vascular damage in a mouse model of diabetic retinopathy: relation to neuronal and glial changes. Invest Ophthalmol Vis Sci 2005, 46:4281-4287.
64. Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA: An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci U S A 1989, 86:4544-4548.
65. Hirschi KK, Rohovsky SA, Beck LH, Smith SR, D'Amore PA: Endothelial cells modulate the proliferation of mural cell precursors via platelet-derived growth factor-BB and heterotypic cell contact. Circ Res 1999, 84:298-305.
66. Darland DC, Massingham LJ, Smith SR, Piek E, Saint-Geniez M, D'Amore PA: Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 2003, 264:275-288.
67. Ejaz S, Chekarova I, Ejaz A, Sohail A, Lim CW: Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes Metab 2008, 10:53-63.
68. Ho AC, Scott IU, Kim SJ, Brown GC, Brown MM, Ip MS, Recchia FM: Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: A report by the American Academy of Ophthalmology. Ophthalmology 2012, 119: 2179-2188.
69. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, Bennett MR: Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 2006, 12:1075-1080.